Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs

Drug Development Research

Volumn 50, Issue 3-4, 2000, Pages 298-308

  Ashani, Yacov ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Cocaine; Detoxification; Muscle relaxants; Organophosphates; Prophylaxis

Indexed keywords

ACETYLCHOLINESTERASE; ANTIDOTE; CHOLINESTERASE; MUSCLE RELAXANT AGENT; ORGANOPHOSPHATE PESTICIDE; PRODRUG;

APNEA; BIOTRANSFORMATION; COCAINE DEPENDENCE; CONTROLLED DRUG RELEASE; DETOXIFICATION; DRUG SAFETY; ENZYME STRUCTURE; PREFORMULATION; PROPHYLAXIS; REVIEW;

EID: 0033809639     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200007/08)50:3/4<298::aid-ddr13>3.0.co;2-x     Document Type: Review

References (89)

1. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase
2. Conserved aromatic residues of the carboxy terminus mediate association of tetramers of human butyrylcholinesterase
3. Inhibition of acetylcholinesterase and butyrylcholinesterase by chlorpyrifos-oxon
4. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice
5. Amino acid residues controlling reactivation of organophosphonyl conjugates of acetylcholinesterase by mono- and bisquaternary oximes
6. Current capabilities in extrapolating from animal to human the capacity of human butyrylcholinesterase to detoxify organophosphates
7. Pharmacokinetics of bambuterol in subjects homozygous for the atypical gene for plasma cholinesterase
8. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats
9. Protection by butyrylcholinesterase against organophosphorus poisoning in non-human primates
10. Reaction of human butyrylcholinesterase (BChE) H117 enzymes with carbamates
11. The plasma cholinesterases: A new perspective
12. The influence of plasma butyrylcholinesterase concentration on the in vitro hydrolysis of cocaine in human plasma
13. Human toxicity of various oximes
14. The use of serum cholinesterase in severe phosphorus posisoning. Personal experience
15. Cholinesterases. Its significance in anaesthetic practice
16. The use of atropine and oximes in organophosphate intoxication: A modified approach
17. The protection of primates against soman poisoning by pretreatment with pyridostigmine
18. Progress in medical defense against nerve agents
19. Injectable local anesthetic antidote
20. Half-life of human serum cholinesterase following blood transfusion
21. Therapy of prolonged apnea after suxamethonium with purified pseudocholinesterase: New data on kinetics of hydrolysis of succinyldicholine and succinylmonocholine and further data on acetyltransferase-polymorphism
22. Enhancing cocaine metabolism with butyrylcholinesterase as treatment strategy
23. Large-scale purification and long-term stability of human butyrylcholinesterase: A potential bioscavenger drug
24. Conversion of of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis
25. The effect of plasma cholinesterase activity on mivacurium infusion rates
26. Kinetics of succinyldithiocholine hydrolysis by serum cholinesterase: Comparison to dibucaine and succinylcholine numbers
27. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice
28. Some effects of 2 mg im atropine and 5 mg im diazepam, separately and combined on human performance
29. New neuromuscular blocking drugs
30. Metabolism of cocaine in man
31. Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA
32. Cholinesterases in plasma. First reported absence of in the Bantu; half life determination
33. Organophosphorous poisoning and anesthesia
34. Amino acid residues involved in the interaction of acetylcholinesterase with the carbamate Ro 02-0683 and bambuterol, and with terbutaline
35. Plasma esterase activity and metabolism of drugs with ester groups
36. N-COMP-A window-based program for noncompartmental analysis of pharmacokinetic data
37. Characterization of O,O-diethylphosphoryl oximes as inhibitors of cholinesterases and substrates of phosphotriesterases
38. Behavioral effects of organophosphate pesticide in man
39. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine
40. Interchain disulfide bonds and subunit organization in human serum cholinesterase
41. Complete amino acid sequence of human serum cholinesterase
42. Cocaine detoxification by human plasma
43. Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstruction
44. Importance of aspartate-70 in organophosphate inhibition oxime reactivation and aging of human butyrylcholinesterase
45. Role of aspartate 70 and tryptophane 82 in binding of succinyldithiocholine to human butyrylcholinesterase
46. Butyrylcholinesterase-catalyzed hydrolysis of aspirin, a negatively charged ester and aspirin-related neutral esters
47. Therapeutic use of butyrylcholinesterase for cocaine intoxication
48. Pathology of nerve agents: Perspectives on medical management
49. Organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase: Synergy results in somanase
50. Inhibition of acetylcholinesterase and butyrylcholinesterase by potato glycoalkaloids
51. Human plasma cholinesterase for antagonism of prolonged mivacurium-induced neuromuscular blockade
52. Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase
53. Enzymatic versus pharmacokinetic antagonism of profound mivacurium-induced neuromuscular blockade
54. Is the recovery profile of mivacurium independent of the rate of decay of its plasma concentration in patients with normal plasma cholinesterase activity?
55. Pharmacokinetics of bambuterol in healthy subjects
56. Comparative use of muscle relaxants and their reversal in three European countries: A survey in France, Germany and Great Britain
57. Half-life of plasma cholinesterase
58. The relation of sex, age, smoking, status, birth rank and parental ages to pseudocholinesterase activity and phenotypes in a sample of Australia Caucasian males
59. Human butyrylcholinesterase as general prophylactic antidote for nerve agent toxicity
60. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase
61. The effect of succinylcholine on atracurium-induced neuromuscular block
62. Chronic central nervous system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects Study Group
63. Neuromuscular blocking agents in the emergency department
64. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drugs
65. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase
66. Role of oligosaccharides in the pharmacokinetics of tissue derived and genetically engineered cholinesterases
67. The use of serum cholinesterase in succinylcholine apnea
68. Serum cholinesterase: Effect on action of suxamethonium following administration to a patient with cholinesterase deficiency
69. Grafting of genetically modified human fetal fibroblasts to produce human butyrylchohnesterase in mice
70. Soman and sarin clinical manifestation and treatment of accidental poisoning by organophosphates
71. Clinical pharmacokinetics of bambuterol
72. Organophosphorus pesticide-induced butyrylcholinestrerase inhibition and potentiation of succinylcholine toxicity in mice
73. Hydrolysis of cocaine in human plasma by cholinesterase
74. Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases
75. Suxamethonium apnea terminated with commercial serum cholinesterase
76. Atomic structure of acetylcholinesterase from Torpedo californica: A prototype acetylcholine binding protein
77. The design and bioactivation of presystemically stable prodrug
78. Genetic factors in Alzheimer's disease
79. 3H-bambuterol, a carbamate prodrug of terbutaline, in blood from humans and laboratory animals in vitro
80. Bambuterol, a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterase in human blood
81. Interaction of bambuterol with human serum cholinesterase of the genotype E(u)E(u) (normal), E(a)E(a) (atypical) and E(u)E(a)
82. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with genotypically normal enzyme
83. Oxime reactivation diethylphosphoryl human butyrylcholinesterase
84. Characteristics of recombinant human butyrylcholinesterase expressed in Bombyx mori expression system
85. Fatal reactions to cocaine
86. Cholinesterases
87. Cholinesterase reactivation in organophosphorus poisoned patients depends on the plasma concentration of the oxime pralidoxime methylsulphate and of the organophosphate
88. Use of cholinesterases as pretreatment drugs for protection of rhesus monkeys against soman toxicity
89. An improved cocaine hydrolysis: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient